Send to

Choose Destination
Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):177-185. doi: 10.15326/jcopdf.4.3.2017.0136.

The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.

Author information

Department of Family and Community Health, University of Minnesota School of Medicine, Minneapolis.
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York.
Department of Preventive Medicine and Environmental Health, University of Kentucky, College of Public Health, Lexington.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor.
Asthma and COPD Program, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Clinical Discovery Unit, Early Clinical Development, AstraZeneca, Cambridge, United Kingdom and Department of Medicine, University of Nebraska Medical Center, Omaha.
COPD Foundation, Washington, D.C.
Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.
Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.


The COPD Foundation Pocket Consultant Guide (PCG) was first released in 2007 as a practice tool for use at point of service for clinicians, especially primary care clinicians diagnosing and treating patients with chronic obstructive pulmonary disease (COPD). Over the years, the PCG has been supplemented with a mobile app that presents the tool in an online smart phone accessible version that also allows the clinician to enter patient specific data for guidance to next steps of diagnosis or management. In November 2016, a new update of the PCG was released that incorporates a flow diagram for stepped care that includes the newest recommendation for diagnosis, assessment and treatment; including the broad use of dual bronchodilator therapy and consideration of asthma COPD overlap syndrome (ACOS). The current controversy regarding when to add inhaled corticosteroids (ICSs) is addressed to support clinical decision making. The PCG comes in 2 versions, one with generic names for COPD drugs available in the United States and one with trade names for those drugs. The update continues to recommend spirometry for those at highest risk, also emphasizing the need to assess symptoms, exacerbation risks and comorbidity before selecting appropriate non-pharmacological as well as pharmacological therapy. The tool is designed to facilitate COPD management in daily practice.


GOLD; care recommendations; chronic obstructive pulmonary disease; copd; guidelines; point of care; primary care

Conflict of interest statement

Barbara P. Yawn reports receiving COPD-related personal fees from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis and COPD-related research grant support from Boehringer-Ingelheim outside the submitted work. Scott Cerreta reports he has nothing to declare. MeiLan Han reports receiving personal fees from Sunovion, Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis and receiving research grant support from Novartis and Sunovion outside the submitted work. David Mannino reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, grants and personal fees from Novartis, personal fees from Amgen, grants and personal fees from Boehringer Ingelheim, personal fees from Merck, personal fees from Forest, personal fees from Up to Date, other from COPD Foundation, personal fees from Schlesinger Law Firm, non-financial support from Sunovion, outside the submitted work. Byron Thomashow reports receiving personal fees from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca, and Novartis outside the submitted work. Robert Wise reports receiving personal fees from AstraZeneca, Boehringer-Ingelheim, Contrafect, GlaxoSmithKline, Merck, Novartis, Pulmonx, Roche-Genentech, Spiration, Sunovion, Teva and research grant support from AstraZeneca, Boehringer-Ingelheim, and GlaxoSmithKline outside the submitted work. Stephen Rennard is employed by AstraZeneca, Cambridge, United Kingdom. He reports receiving personal fees from Baxter, AstraZeneca, Dailchi Sankyo, Forest, Penn Technology, Novartis, Pulmirix, and Takeda as well as research grant support from Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Nycomed, Astra-Zeneca, Centocor, and Almirall outside the submitted work. Ravi Kahlan reports personal fees from Forest Laboratories, Boehringer Ingelheim, Merck, Smith Medical, AstraZeneca, CVS Caremark, and Aptus Health, as well as research grant support from Boehringer Ingelheim, GlaxoSmithKline, PneumRx (BTG), Spiration, all outside the submitted work

Publication type

Publication type

Supplemental Content

Full text links

Icon for COPD Foundation Icon for PubMed Central
Loading ...
Support Center